ÂÜÀòÂÒÂ×

Paul Fleming is a highly experienced chemist and biologist with a robust background in drug discovery and development. Currently serving as the Senior Director and Head of Research at Akebia Therapeutics since June 2021, Paul leads a research group focused on developing HIF stabilizers, protein hydroxylase inhibitors, and immunomodulators. Prior roles include Director of Chemistry at Civetta Therapeutics and Akebia Therapeutics, where Paul specialized in structure-based design of small molecule modulators and selective prolyl hydroxylase inhibitors. Notable positions also include Director of Chemistry at Blueprint Medicines, contributing to the development of kinase inhibitors, and a Senior Scientist II at Takeda, where Paul led oncology and immunology programs. Paul began a career in medicinal chemistry at Millennium Pharmaceuticals, advancing projects that led to significant therapeutic candidates. Academic credentials include a PhD in Organic Chemistry from the University of Washington and a Bachelor of Science in Chemistry from the University of Oregon.